COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention

On 17 May 2021 the FDA issued this final guidance for industry.

FDA is issuing this guidance to provide recommendations to sponsors of master protocols evaluating drugs for the treatment or prevention of COVID 19. This guidance document is being implemented immediately, but it remains subject to comment in accordance with the Agency’s good guidance practices.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /